In vitro Antifungal Activity of a Novel Antimicrobial Peptide AMP-17 Against Planktonic Cells and Biofilms of Cryptococcus neoformans

References

• Zavala S, Baddley JW. Cryptococcosis. Semin Respir Crit Care Med. 2020;41(1):69–79. doi:10.1055/s-0039-3400280
   PubMed Web of Science ®Google Scholar
• Coelho C, Bocca AL, Casadevall A. The intracellular life of Cryptococcus neoformans. Annu Rev Pathol. 2014;9(1):219–238. doi:10.1146/annurev-pathol-012513-104653
   Web of Science ®Google Scholar
• Kronstad JW, Attarian R, Cadieux B, et al. Expanding fungal pathogenesis: Cryptococcus breaks out of the opportunistic box. Nat Rev Microbiol. 2011;9(3):193–203. doi:10.1038/nrmicro2522
   PubMed Web of Science ®Google Scholar
• Shorman M, Evans D, Gibson C, et al. Cases of disseminated cryptococcosis in intravenous drug abusers without HIV infection: a new risk factor? Med Mycol Case Rep. 2016;14:17–19. doi:10.1016/j.mmcr.2016.12.003
   Google Scholar
• Williamson PR, Jarvis JN, Panackal AA, et al. Cryptococcal meningitis epidemiology, immunology, diagnosis and therapy. Nat Rev Neurol. 2017;13(1):13–24. doi:10.1038/nrneurol.2016.167
   PubMed Web of Science ®Google Scholar
• Santos-Gandelman J, Machado-Silva A. Drug development for cryptococcosis treatment: what can patents tell us? Mem Inst Oswaldo Cruz. 2019;114:e180391. doi:10.1590/0074-02760180391
   Web of Science ®Google Scholar
• Rajasingham R, Smith RM, Park BJ, et al. Global burden of disease of HIV-associated cryptococcal meningitis: an updated analysis. Lancet Infect Dis. 2017;17(8):873–881. doi:10.1016/S1473-3099(17)30243-8
   PubMed Web of Science ®Google Scholar
• Perfect JR, Dismukes WE, Dromer F, et al. Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis. 2010;50(3):291–322. doi:10.1086/649858
   PubMed Web of Science ®Google Scholar
• Garvey EP, Sharp AD, Warn PA, et al. The novel fungal CYP51 inhibitor VT-1598 is efficacious alone and in combination with liposomal amphotericin B in a murine model of cryptococcal meningitis. J Antimicrob Chemoth. 2018;73(10):2815–2822. doi:10.1093/jac/dky242
   PubMed Web of Science ®Google Scholar
• Loyse A, Thangaraj H, Easterbrook P, et al. Cryptococcal meningitis: improving access to essential antifungal medicines in resource-poor countries. Lancet Infect Dis. 2013;13(7):629–637. doi:10.1016/S1473-3099(13)70078-1
   PubMed Web of Science ®Google Scholar
• Kong Q, Cao Z, Lv N, et al. Minocycline and fluconazole have a synergistic effect against Cryptococcus neoformans both in vitro and in vivo. Front Microbiol. 2020;11:836. doi:10.3389/fmicb.2020.00836
   Web of Science ®Google Scholar
• May RC, Stone NR, Wiesner DL, et al. Cryptococcus: from environmental saprophyte to global pathogen. Nat Rev Microbiol. 2016;14(2):106–117. doi:10.1038/nrmicro.2015.6
   PubMed Web of Science ®Google Scholar
• Datta A, Yadav V, Ghosh A, et al. Mode of action of a designed antimicrobial peptide: high potency against Cryptococcus neoformans. Biophys J. 2016;111(8):1724–1737. doi:10.1016/j.bpj.2016.08.032
   Web of Science ®Google Scholar
• Mayer FL, Kronstad JW. Disarming fungal pathogens: Bacillus safensis inhibits virulence factor production and biofilm formation by Cryptococcus neoformans and Candida albicans. mBio. 2017;8(5):e01537–17. doi:10.1128/mBio.01537-17
   Web of Science ®Google Scholar
• Ramage G, Williams C. Chapter two–the clinical importance of fungal biofilms. Adv Appl Microbiol. 2013;84(4):27–83. doi:10.1016/B978-0-12-407673-0.00002-3
   Web of Science ®Google Scholar
• Kumari P, Mishra R, Arora N, et al. Antifungal and anti-biofilm activity of essential oil active components against Cryptococcus neoformans and Cryptococcus laurentii. Front Microbiol. 2017;8:2161. doi:10.3389/fmicb.2017.02161
   PubMed Web of Science ®Google Scholar
• Martinez LR, Casadevall A. Specific antibody can prevent fungal biofilm formation and this effect correlates with protective efficacy. Infect Immun. 2005;73(10):6350–6362. doi:10.1128/IAI.73.10.6350-6362.2005
   PubMed Web of Science ®Google Scholar
• Casadevall A, Steenbergen JN, Nosanchuk JD. ‘Ready made’ virulence and ‘dual use’ virulence factors in pathogenic environmental fungi–the Cryptococcus neoformans paradigm. Curr Opin Microbiol. 2003;6(4):332–337. doi:10.1016/s1369-5274(03)00082-1
   PubMed Web of Science ®Google Scholar
• Hall-Stoodley L, Costerton JW, Stoodley P. Bacterial biofilms: from the natural environment to infectious diseases. Nat Rev Microbiol. 2004;2(2):95–108. doi:10.1038/nrmicro821
   PubMed Web of Science ®Google Scholar
• Martinez LR, Casadevall A. Cryptococcus neoformans cells in biofilms are less susceptible than planktonic cells to antimicrobial molecules produced by the innate immune system. Infect Immun. 2006;74(11):6118–6123. doi:10.1128/IAI.00995-06
   Web of Science ®Google Scholar
• Jhong JH, Chi YH, Li WC, et al. dbAMP: an integrated resource for exploring antimicrobial peptides with functional activities and physicochemical properties on transcriptome and proteome data. Nucleic Acids Res. 2019;47(D1):D285–D297. doi:10.1093/nar/gky1030
   Web of Science ®Google Scholar
• Fjell CD, Hiss JA, Hancock RE, et al. Designing antimicrobial peptides: form follows function [published correction appears in Nat Rev Drug Discov. 2012 Feb;11(2):168]. Nat Rev Drug Discov. 2011;11(1):37–51. doi:10.1038/nrd3591
   PubMed Web of Science ®Google Scholar
• van der Does AM, Hiemstra PS, Mookherjee N. Antimicrobial host defence peptides: immunomodulatory functions and translational prospects. Adv Exp Med Biol. 2019;1117:149–171. doi:10.1007/978-981-13-3588-4_10
   PubMed Web of Science ®Google Scholar
• Xiu JF, Wang T, Wang Y, et al. Histological observation and expression patterns of antimicrobial peptides during fungal infection in Musca domestica (Diptera: muscidae) larvae. Braz Arch Biol Technol. 2016;59:1–13. doi:10.1590/1678-4324-2016160147
   Web of Science ®Google Scholar
• Guo G, Tao R, Li Y, et al. Identification and characterization of a novel antimicrobial protein from the housefly Musca domestica. Biochem Biophys Res Commun. 2017;490(3):746–752. doi:10.1016/j.bbrc.2017.06.112
   Web of Science ®Google Scholar
• Yang LB, Guo G, Zhao XY, et al. Antifungal activity and physicochemical properties of a novel antimicrobial protein AMP-17 from Musca domestica. Pol J Microbiol. 2019;68(3):383–390. doi:10.33073/pjm-2019-041
   Web of Science ®Google Scholar
• Ma H, Zhao X, Yang L, et al. Antimicrobial peptide AMP-17 affects Candida albicans by disrupting its cell wall and cell membrane integrity. Infect Drug Resist. 2020;13:2509–2520. doi:10.2147/IDR.S250278
   Web of Science ®Google Scholar
• CLSI. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts: Approved Standard-Third Edition. M27-A3 Ed. (CLSI, Ed.). Wayne, PA: Clinical and Laboratory Standards Institute; 2008.
   Google Scholar
• Seyedjavadi SS, Khani S, Eslamifar A, et al. The antifungal peptide MCh-AMP1 derived from Matricaria chamomilla inhibits Candida albicans growth via inducing ROS generation and altering fungal cell membrane permeability. Front Microbiol. 2020;10:3150. doi:10.3389/fmicb.2019.03150
   PubMed Web of Science ®Google Scholar
• Lemos ASO, Florêncio JR, Pinto NCC, et al. Antifungal activity of the natural coumarin scopoletin against planktonic cells and biofilms from a multidrug-resistant Candida tropicalis strain. Front Microbiol. 2020;11:1525. doi:10.3389/fmicb.2020.01525
   Web of Science ®Google Scholar
• Yang Y, Wang C, Gao N, et al. A novel dual-targeted α-Helical peptide with potent antifungal activity against fluconazole-resistant Candida albicans clinical isolates. Front Microbiol. 2020;11:548620. doi:10.3389/fmicb.2020.548620
   Web of Science ®Google Scholar
• Li L, Sun J, Xia S, et al. Mechanism of antifungal activity of antimicrobial peptide APP, a cell-penetrating peptide derivative, against Candida albicans: intracellular DNA binding and cell cycle arrest. Appl Microbiol Biotechnol. 2016;100(7):3245–3253. doi:10.1007/s00253-015-7265-y
   Web of Science ®Google Scholar
• Pierce CG, Uppuluri P, Tristan AR, et al. A simple and reproducible 96-well plate-based method for the formation of fungal biofilms and its application to antifungal susceptibility testing. Nat Protoc. 2008;3(9):1494–1500. doi:10.1038/nport.2008.141
   PubMed Web of Science ®Google Scholar
• Brilhante RSN, Gotay WJP, Pereira VS, et al. Antifungal activity of promethazine and chlorpromazine against planktonic cells and biofilms of Cryptococcus neoformans/Cryptococcus gattii complex species. Med Mycol. 2020;58(7):906–912. doi:10.1093/mmy/myz140
   Web of Science ®Google Scholar
• Martinez LR, Casadevall A. Cryptococcus neoformans biofilm formation depends on surface support and carbon source and reduces fungal cell susceptibility to heat, cold, and UV light. Appl Environ Microbiol. 2007;73(14):4592–4601. doi:10.1128/AEM.02506-06
   Web of Science ®Google Scholar
• Quinteros MA, Galera ILD, Tolosa J, et al. Novel antifungal activity of oligostyrylbenzenes compounds on Candida tropicalis biofilms. Med Mycol. 2021;59(3):244–252. doi:10.1093/mmy/myaa046
   Web of Science ®Google Scholar
• Ravi S, Pierce C, Witt C, et al. Biofilm formation by Cryptococcus neoformans under distinct environmental conditions. Mycopathologia. 2009;167(6):307–314. doi:10.1007/s11046-008-9180-6
   Web of Science ®Google Scholar
• Liu W, Wu Z, Mao C, et al. Antimicrobial peptide Cec4 eradicates the bacteria of clinical carbapenem-resistant Acinetobacter baumannii biofilm. Front Microbiol. 2020;11:1532. doi:10.3389/fmicb.2020.01532
   PubMed Web of Science ®Google Scholar
• Spec A, Powderly WG. Cryptococcal meningitis in AIDS. Handb Clin Neurol. 2018;152:139–150. doi:10.1016/B978-0-444-63849-6.00011-6
   Google Scholar
• Lawrence DS, Boyer-Chammard T, Jarvis JN. Emerging concepts in HIV-associated cryptococcal meningitis. Curr Opin Infect Dis. 2019;32(1):16–23. doi:10.1097/QCO.0000000000000514
   Web of Science ®Google Scholar
• Smith KD, Achan B, Hullsiek KH, et al. Increased antifungal drug resistance in clinical isolates of Cryptococcus neoformans in Uganda. Antimicrob Agents Chemother. 2015;59(12):7197–7204. doi:10.1128/AAC.01299-15
   PubMed Web of Science ®Google Scholar
• Martinez LR, Casadevall A. Biofilm formation by Cryptococcus neoformans. Microbiol Spectr. 2015;3(3). doi:10.1128/microbiolspec.MB-0006-2014
   Google Scholar
• Raman N, Lee MR, Rodríguez López AL, et al. Antifungal activity of a β-peptide in synthetic urine media: toward materials-based approaches to reducing catheter-associated urinary tract fungal infections. Acta Biomater. 2016;43:240–250. doi:10.1016/j.actbio.2016.07.016
   Web of Science ®Google Scholar
• Ma L, Ye X, Sun P, et al. Antimicrobial and antibiofilm activity of the EeCentrocin 1 derived peptide EC1-17KV via membrane disruption. EBioMedicine. 2020;55:102775. doi:10.1016/j.ebiom.2020.102775
   Web of Science ®Google Scholar
• Yang Y, Chen F, Chen HY, et al. A Novel antimicrobial peptide scyreprocin from mud crab Scylla paramamosain showing potent antifungal and anti-biofilm activity. Front Microbiol. 2020;11:1589. doi:10.3389/fmicb.2020.01589
   Web of Science ®Google Scholar
• Tan L, Bai L, Wang L, et al. Antifungal activity of spider venom-derived peptide lycosin-I against Candida tropicalis. Microbiol Res. 2018;216:120–128. doi:10.1016/j.micres.2018.08.012
   Web of Science ®Google Scholar
• Cortés JCG, Curto MÁ, Carvalho VSD, et al. The fungal cell wall as a target for the development of new antifungal therapies. Biotechnol Adv. 2019;37(6):107352. doi:10.1016/j.biotechadv.2019.02.008
   PubMed Web of Science ®Google Scholar
• van der Weerden NL, Bleackley MR, Anderson MA. Properties and mechanisms of action of naturally occurring antifungal peptides. Cell Mol Life Sci. 2013;70(19):3545–3570. doi:10.1007/s00018-013-1260-1
   PubMed Web of Science ®Google Scholar
• Le CF, Fang CM, Sekaran SD. Intracellular targeting mechanisms by antimicrobial peptides. Antimicrob Agents Chemother. 2017;61(4):e02340–16. doi:10.1128/AAC.02340-16
   PubMed Web of Science ®Google Scholar
• Tavares ER, Gionco B, Morguette AEB, et al. Phenotypic characteristics and transcriptome profile of Cryptococcus gattii biofilm. Sci Rep. 2019;9(1):6438. doi:10.1038/s41598-019-42896-2
   PubMed Web of Science ®Google Scholar
• Korem M, Kagan S, Polacheck I. The effect of novel heterocyclic compounds on cryptococcal biofilm. J Fungi. 2017;3(3):42. doi:10.3390/jof3030042
   Web of Science ®Google Scholar
• Martinez LR, Casadevall A. Susceptibility of Cryptococcus neoformans biofilms to antifungal agents in vitro. Antimicrob Agents Chemother. 2006;50(3):1021–1033. doi:10.1128/AAC.50.3.1021-1033.2006
   Web of Science ®Google Scholar
• Vecchiarelli A. Immunoregulation by capsular components of Cryptococcus neoformans. Med Mycol. 2000;38(6):407–417. doi:10.1080/mmy.38.6.407.417
   PubMed Web of Science ®Google Scholar
• Al-Fattani MA, Douglas LJ. Penetration of candida biofilms by antifungal agents. Antimicrob Agents Chemother. 2004;48(9):3291–3297. doi:10.1128/AAC.48.9.3291-3297.2004
   PubMed Web of Science ®Google Scholar
• Chandra J, Kuhn DM, Mukherjee PK, et al. Biofilm formation by the fungal pathogen Candida albicans: development, architecture, and drug resistance. J Bacteriol. 2001;183(18):5385–5394. doi:10.1128/JB.183.18.5385-5394.2001
   PubMed Web of Science ®Google Scholar